# NCT01614821 (NCT01614821)

> Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01614821
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Waldenstrom's Macroglobulinemia
- Interventions: PCI-32765
- Enrollment: 63
- Primary outcome: Overall Response Rate

## Indexed commentary on NCT01614821 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct01614821